Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with leukemia: drug trial targets cancer control

NCT ID NCT07354074

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a drug called asciminib in children aged 1 to 18 with a specific leukemia (Ph+ CML-CP). The goal is to see if the drug can control the cancer by reducing the number of cancer cells. About 50 children will take the drug, and researchers will check how well it works and if it is safe. This is not a cure, as children will need to keep taking the drug to manage their disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic myelogenous leukemia, BCR-ABL1 positive leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOGENOUS LEUKEMIA LEUKEMIA, MYELOGENOUS, CHRONIC, PHILADELPHIA CHROMOSOME POSITIVE

Contacts and locations

Locations

  • Columbia University Medical Center New York Presbyterian

    RECRUITING

    New York, New York, 10032, United States

  • Novartis Investigative Site

    RECRUITING

    Brisbane, Queensland, 4101, Australia

  • Novartis Investigative Site

    RECRUITING

    North Adelaide, South Australia, 5066, Australia

  • Novartis Investigative Site

    RECRUITING

    Edmonton, Alberta, T6G 1C9, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H3T 1C5, Canada

  • Novartis Investigative Site

    RECRUITING

    Zhengzhou, Henan, 450003, China

  • Novartis Investigative Site

    RECRUITING

    Tianjin, 300020, China

  • Novartis Investigative Site

    RECRUITING

    Marseille, 13885, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75019, France

  • Novartis Investigative Site

    RECRUITING

    Poitiers, 86021, France

  • Novartis Investigative Site

    RECRUITING

    Strasbourg, 67000, France

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    RECRUITING

    Yokohama, Kanagawa, 232-8555, Japan

  • Novartis Investigative Site

    RECRUITING

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    RECRUITING

    Saitama, 330 8777, Japan

  • Novartis Investigative Site

    RECRUITING

    Utrecht, 3584 CS, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Gdansk, 80-214, Poland

  • Novartis Investigative Site

    RECRUITING

    Wroclaw, 50-556, Poland

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28009, Spain

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Seattle Childrens Hospital

    RECRUITING

    Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.